Skip to main content

Advertisement

SpringerLink
Log in

Gout and coronary artery disease: Epidemiologic clues

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Gout is the leading cause of inflammatory arthritis, typically affecting men and characterized by intermittent, abrupt onset of intense inflammation. The association between gout, atherosclerosis, and vascular disease has been noted in medical literature since the end of the 19th century, yet it has not been well studied. This review critically appraises the few epidemiologic studies that ask if gout is a risk factor for coronary artery disease. An exhaustive literature search using search engines and cross-referencing found four major studies and several smaller studies that have evaluated gout as a risk factor for coronary artery disease. The available studies were too heterogeneous to permit formal metaanalysis. Although there are gaps in evidence pointing to a causative pathway, overall, evidence exists for a relationship between gouty arthritis and coronary artery disease independent of traditional risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Roberts W: Gout. In A System of Medicine by Many Writers. Edited by Allbutt T. London: Macmillan; 1897:160.

    Google Scholar 

  2. Benedek TG: Correlations of serum uric acid and lipid concentrations in normal, gouty, and atherosclerotic men. Ann Intern Med 1967, 66:851–861.

    PubMed  CAS  Google Scholar 

  3. Benedek TG, Sunder JH: Comparisons of serum lipid and uric acid content in white and Negro men. Am J Med Sci. 1970, 260:331–340.

    Article  PubMed  CAS  Google Scholar 

  4. Ask-Upmark E, Adner L: Coronary infarction and gout. Acta Med Scand 1950, 139:1–6.

    Google Scholar 

  5. Gardner MJ, Power C, Barker DJ, Padday R: The prevalence of gout in three English towns. Int J Epidemiol 1982, 11:71–75.

    Article  PubMed  CAS  Google Scholar 

  6. Choi HK, Mount DB, Reginato AM: Pathogenesis of gout. Ann Intern Med 2005, 143:499–516.

    PubMed  CAS  Google Scholar 

  7. Krishnan E, Griffith C, Kwoh C: Burden of illness from gout in ambulatory care in the United States. Arthritis Rheum 2005, 52:S656.

    Google Scholar 

  8. Baker JF, Krishnan E, Chen L, Schumacher HR: Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005, 118:816–826.

    Article  PubMed  CAS  Google Scholar 

  9. Abbott RD, Brand FN, Kannel WB, Castelli WP: Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988, 41:237–242.

    Article  PubMed  CAS  Google Scholar 

  10. Gelber AC, Klag MJ, Mead LA, et al.: Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med 1997, 157:1436–1440.

    Article  PubMed  CAS  Google Scholar 

  11. Krishnan E, Baker JF, Furst DE, Schumacher HR: Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006, 54:2688–2696.

    Article  PubMed  CAS  Google Scholar 

  12. Choi HK, Curhan G: Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116:894–900.

    Article  PubMed  Google Scholar 

  13. D’Agostino RB, Kannel WB: Epidemiological background and design: the Framingham Study. Proceedings of the American Statistical Association sesquicentennial invited paper sessions. Alexandria, Va: American Statistical Association; 1989:707–718.

    Google Scholar 

  14. Wallace SL, Robinson H, Masi AT, et al.: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895–900.

    Article  PubMed  CAS  Google Scholar 

  15. Rho YH, Choi SJ, Lee YH, et al.: The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005, 20:1029–1033.

    Article  PubMed  CAS  Google Scholar 

  16. Wluka AE, Ryan PF, Miller AM, et al.: Post-cardiac transplantation gout: incidence of therapeutic complications. J Heart Lung Transplant 2000, 19:951–956.

    Article  PubMed  CAS  Google Scholar 

  17. Fam AG: Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002, 29:1350–1355.

    PubMed  CAS  Google Scholar 

  18. Muscelli E, Natali A, Bianchi S, et al.: Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996, 9:746–752.

    Article  PubMed  CAS  Google Scholar 

  19. Wannamethee SG, Shaper AG, Whincup PH: Serum urate and the risk of major coronary heart disease events. Heart 1997, 78:147–153.

    PubMed  CAS  Google Scholar 

  20. Krishnan E, Svendsen K, Neaton J, et al.: Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008 (in press).

  21. Mikuls TR, Farrar JT, Bilker WB, et al.: Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 2005, 64:267–272.

    Article  PubMed  CAS  Google Scholar 

  22. Chen SY, Chen CL, Shen ML: Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study. Clin Rheumatol 2007, 26:308–313.

    Article  PubMed  Google Scholar 

  23. Ferns GA, Lanham J, Dieppe P, Galton DJ: A DNA polymorphism of an apoprotein gene associates with the hypertriglyceridaemia of primary gout. Hum Genet 1988, 78:55–59.

    Article  PubMed  CAS  Google Scholar 

  24. Moriwaki Y, Yamamoto T, Takahashi S, et al.: Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia. Ann Rheum Dis 1995, 54:351–354.

    Article  PubMed  CAS  Google Scholar 

  25. Choi HK, Atkinson K, Karlson EW, Curhan G: Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005, 165:742–748.

    Article  PubMed  Google Scholar 

  26. Evaluation of a new oral diuretic agent. Furosemide (Lasix) JAMA 1967, 200:979–980.

  27. Sanderson EW: Gout as a complication of oral diuretic therapy. S D J Med 1966, 19:13–18.

    PubMed  CAS  Google Scholar 

  28. Velayos EE, Smyth CJ: Urate diuretic therapy in chronic gout; a comparative study of probenecid and sulfinpyrazone. Arch Intern Med 1965, 116:212–219.

    PubMed  CAS  Google Scholar 

  29. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894:i–xii, 1–253.

  30. Engelhardt HT, Wagner EL: Gout, diabetes mellitus and obesity, a poorly appreciated syndrome. South Med J 1950, 43:51–53.

    PubMed  CAS  Google Scholar 

  31. Traut EF, Knight AA, Szanto PB, Passerelli EW: Specific vascular changes in gout. J Am Med Assoc 1954, 156:591–593.

    PubMed  CAS  Google Scholar 

  32. Mikuls TR, Saag KG: New insights into gout epidemiology. Curr Opin Rheumatol 2006, 18:199–203.

    Article  PubMed  Google Scholar 

  33. Alderman MH: Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002, 2:126–130.

    Article  PubMed  CAS  Google Scholar 

  34. Nakagawa T, Kang DH, Feig D, et al.: Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int 2006, 69:1722–1725.

    Article  PubMed  CAS  Google Scholar 

  35. Ishizaka N, Ishizaka Y, Toda E, et al.: Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis 2007, 192:131–137.

    Article  PubMed  CAS  Google Scholar 

  36. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685–1695.

    Article  PubMed  CAS  Google Scholar 

  37. Kuller LH, Tracy RP: The role of inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol 2000, 20:901.

    PubMed  CAS  Google Scholar 

  38. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.

    Article  PubMed  CAS  Google Scholar 

  39. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979.

    Article  PubMed  CAS  Google Scholar 

  40. Ridker PM: Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999, 10(Suppl 1):S9–12.

    PubMed  Google Scholar 

  41. Alexander RW: Inflammation and coronary artery disease. N Engl J Med 1994, 331:468–469.

    Article  PubMed  CAS  Google Scholar 

  42. Tiong AY, Brieger D: Inflammation and coronary artery disease. Am Heart J 2005, 150:11–18.

    Article  PubMed  Google Scholar 

  43. Crea F, Biasucci LM, Buffon A, et al.: Role of inflammation in the pathogenesis of unstable coronary artery disease. Am J Cardiol 1997, 80:10E–16E.

    Article  PubMed  CAS  Google Scholar 

  44. Pascual E: Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991, 34:141–145.

    Article  PubMed  CAS  Google Scholar 

  45. Dalbeth N, Haskard DO: Mechanisms of inflammation in gout. Rheumatology (Oxford) 2005, 44:1090–1096.

    Article  CAS  Google Scholar 

  46. Dessein PH, Joffe BI, Veller MG, et al.: Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005, 32:435–442.

    PubMed  Google Scholar 

  47. Madamanchi NR, Vendrov A, Runge MS: Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:29–38.

    Article  PubMed  CAS  Google Scholar 

  48. Madamanchi NR, Hakim ZS, Runge MS: Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost 2005, 3:254–267.

    Article  PubMed  CAS  Google Scholar 

  49. Saliaris AP, Amado LC, Minhas KM, et al.: Chronic allopurinol administration ameliorates maladaptive alterations in calcium cycling proteins and {beta}-adrenergic hyporesponsiveness in heart failure. Am J Physiol Heart Circ Physiol 2007, 292:H1328–H1335.

    Article  PubMed  CAS  Google Scholar 

  50. George J, Carr E, Davies J, et al.: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006, 114:2508–2516.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MPhil S709 BST South, 3500 Terrace Street, Pittsburgh, PA, 15215, USA

    Eswar Krishnan

Authors
  1. Eswar Krishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eswar Krishnan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krishnan, E. Gout and coronary artery disease: Epidemiologic clues. Curr Rheumatol Rep 10, 249–255 (2008). https://doi.org/10.1007/s11926-008-0039-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0039-0

Keywords

Search

Navigation